Lexicon Pharmaceuticals | LXRX

Peers Price Chg Day Year Date
Abbott 132.25 -0.69 -0.52% 13.61% Sep/08
Acadia Pharmaceuticals 25.38 0.12 0.48% 60.94% Sep/08
Agios Pharmaceuticals 36.41 0.40 1.11% -17.12% Sep/08
Alnylam Pharmaceuticals 455.03 3.03 0.67% 79.74% Sep/08
AstraZeneca 11,970.00 -120.00 -0.99% -5.84% Sep/08
BioMarin Pharmaceutical 56.38 -1.39 -2.41% -33.14% Sep/08
Halozyme Therapeutics 75.85 0.92 1.23% 28.04% Sep/08
Illumina 98.18 -0.75 -0.76% -19.88% Sep/08
Insmed 146.68 1.58 1.09% 104.23% Sep/08
Ironwood Pharmaceuticals 1.13 -0.03 -2.16% -71.61% Sep/08
J&J 178.18 -0.25 -0.14% 6.93% Sep/08
Eli Lilly 738.59 11.38 1.56% -18.68% Sep/08
MacroGenics 1.76 -0.24 -12.00% -48.99% Sep/08
MannKind 5.57 0.03 0.54% -8.69% Sep/08
Merck 84.09 -0.62 -0.73% -27.09% Sep/08
Moderna 24.83 -0.31 -1.23% -67.60% Sep/08
Novartis 102.32 -1.66 -1.60% 2.73% Sep/08
PTC Therapeutics 56.95 -0.31 -0.54% 81.25% Sep/08
Ultragenyx Pharmaceutical 31.51 -0.31 -0.97% -43.53% Sep/08
Sarepta Therapeutics 17.60 -1.11 -5.93% -86.22% Sep/08
Thermo Fisher Scientific 487.65 -4.95 -1.00% -21.35% Sep/08
United Therapeutics 394.62 -5.90 -1.47% 13.17% Sep/08

Indexes Price Day Year Date
USND 21799 98.31 0.45% 29.10% Sep/08
US2000 2396 5.00 0.21% 14.22% Sep/08

Lexicon Pharmaceuticals traded at $2.07 this Tuesday April 9th, decreasing $0.02 or 0.96 percent since the previous trading session. Looking back, over the last four weeks, Lexicon Pharmaceuticals lost 26.33 percent. Over the last 12 months, its price fell by 12.29 percent. Looking ahead, we forecast Lexicon Pharmaceuticals to be priced at 2.05 by the end of this quarter and at 2.00 in one year, according to Trading Economics global macro models projections and analysts expectations.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for human diseases. The Company's drug programs include Sotagliflozin, LX9211 and LX2761. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.